Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TECH

TECH - Bio-Techne Corp Stock Price, Fair Value and News

$65.55-2.68 (-3.93%)
Market Closed

31/100

TECH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

31/100

TECH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$54.53

Target 3M

$62.91

Target 6M

$58.07

TECH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TECH Price Action

Last 7 days

-8.2%

Last 30 days

10.7%

Last 90 days

7.5%

Trailing 12 Months

-12.1%

TECH RSI Chart

TECH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TECH Valuation

Market Cap

10.2B

Price/Earnings (Trailing)

130.97

Price/Sales (Trailing)

8.39

EV/EBITDA

44.8

Price/Free Cashflow

45.58

TECH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$54.53

Target 3M

$62.91

Target 6M

$58.07

TECH Fundamentals

TECH Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

-1%

Rev. Growth (Qtr)

-9.59%

TECH Earnings

Earnings (TTM)

78.0M

Earnings Growth (Yr)

13.65%

Earnings Growth (Qtr)

316%

TECH Profitability

EBT Margin

8.74%

Return on Equity

3.97%

Return on Assets

3.09%

Free Cashflow Yield

2.19%

TECH Investor Care

Dividend Yield

0.53%

Dividend/Share (TTM)

0.32

Buy Backs (1Y)

1.94%

Diluted EPS (TTM)

0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.2B1.2B1.2B0
20241.2B1.2B1.2B1.2B
20231.1B1.1B1.1B1.1B
20221.1B1.1B1.1B1.1B
2021847.8M931.0M984.6M1.0B
2020754.5M738.7M759.6M799.0M
2019702.6M714.0M734.3M744.7M
2018619.3M643.0M661.4M681.7M
2017541.2M563.0M577.0M599.4M
2016481.9M499.0M517.2M528.1M
2015427.1M452.2M456.1M465.1M
2014344.7M357.8M380.6M408.5M
2013309.8M310.6M321.2M330.2M
2012313.9M314.6M312.0M312.4M
2011278.6M290.0M299.6M306.6M
2010000272.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Bio-Techne Corp

TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEbio-techne.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3050

Bio-Techne Corp Frequently Asked Questions

TECH is the stock ticker symbol of Bio-Techne Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bio-Techne Corp is 10.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TECH's fair value in chart for subscribers.

The fair value guage provides a quick view whether TECH is over valued or under valued. Whether Bio-Techne Corp is cheap or expensive depends on the assumptions which impact Bio-Techne Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TECH.

As of Wed Jan 28 2026, TECH's PE ratio (Price to Earnings) is 130.97 and Price to Sales (PS) ratio is 8.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TECH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Bio-Techne Corp has provided 0.122 (multiply by 100 for percentage) rate of return.